PSCA and Oct-4 Expression in the Benign and Malignant Lesions of Gallbladder: Implication for Carcinogenesis, Progression, and Prognosis of Gallbladder Adenocarcinoma

Table 3

Relationship between PSCA and Oct-4 expression, clinicopathological characteristics, and average survival of gallbladder adenocarcinoma patients.

Clinicopathological characteristics	Samples (𝑛)	Average survival (month)	𝑃 value
Sex
Male	19	10.0 (4–16)	0.910
Female	48	10.0 (4–18)
Age (years)
≤45	11	8.0 (4–14)	0.121
>45	56	10.0 (4–18)
Pathological types
Adenoma	8	12.0 (8–18)	0.031
Well	20	10.0 (4–18)
Moderately	20	10.0 (4–18)
Poorly	12	8.0 (4–10)
Mucinous A.	7	10.0 (6–16)
Tumor size (cm)
<2	20	14.0 (4–18)	0.003
≥2	47	8.0 (4–18)
Lymph node metastasis
No	36	12.0 (4–18)	0.005
Yes	31	8.0 (4–18)
T stages
T1	10	12.6 (6–18)	0.003
T2	26	11.4 (4–18)
T3	23	9.5 (4–18)
T4	8	7.0 (4–10)
Operative procedure
Radical	26	12.7 (4–18)	<0.001
Nonradical	41	8.9 (4–16)
PSCA
+	35	9.3 (4–18)	0.013
−	32	11.6 (4–18)
Oct-4
+	37	9.5 (4–18)	0.029
−	30	11.5 (4–18)
PSCA + Oct-4
PSCA (+) Oct-4 (+)	24	8.9 (4–18)	0.021
PSCA (+) Oct-4 (−)	11	10.7 (4–16)
PSCA (−) Oct-4 (+)	13	9.7 (4–16)
PSCA (−) Oct-4 (−)	19	12.5 (6–18)